Oxecta® (oxycodone HCl, USP) Tablets CII are now commercially available from Pfizer, Inc. Oxecta®, which utilizes Acura’s Aversion® Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg dosage strengths. Full prescribing information can be accessed by clicking here.
Acura has entered into a license agreement with King Pharmaceuticals Research & Development, Inc., a subsidiary of Pfizer, Inc. to develop and commercialize opioid analgesic products utilizing our proprietary Aversion® Technology, including Oxecta® Tablets.
Acura’s strategy includes continued investment in novel solutions to prescription drug abuse. We have four issued U.S. patents covering our Aversion® Technology with numerous US and international patent applications pending.